Li Nuannuan, Sun Yiying, Fu Yuanlei, Sun Kaoxiang
Key Laboratory of Molecular Pharmacology and Drug Evaluation (Yantai University), School of Pharmacy, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, Ministry of Education, Yantai University, Yantai, China.
Shandong International Biotechnonlogy Park Development Co. Ltd, Yantai, China.
Front Pharmacol. 2021 Dec 24;12:734443. doi: 10.3389/fphar.2021.734443. eCollection 2021.
RNA-based therapies have been promising method for treating all kinds of diseases, and four siRNA-based drugs and two mRNA-based drugs have been approved and are on the market now. However, none of them is applied for cancer treatment. This is not only because of the complexity of the tumor microenvironment, but also due to the intrinsic obstacles of RNAs. Until now, all kinds of strategies have been developed to improve the performance of RNAs for cancer therapy, especially the nanoparticle-based ones using biogenic materials. They are much more compatible with less toxicity compared to the ones using synthetic polymers, and the most widely studied biogenic materials are oligonucleotides, exosomes, and cell membranes. Particular characteristics make them show different capacities in internalization and endosomal escape as well as specific targeting. In this paper, we systematically summarize the RNA-based nano-delivery systems using biogenic materials for cancer therapy, and we believe this review will provide a valuable reference for researchers involved in the field of biogenic delivery and RNA-based therapies for cancer treatment.
基于RNA的疗法一直是治疗各类疾病的一种有前景的方法,目前已有四种基于小干扰RNA(siRNA)的药物和两种基于信使核糖核酸(mRNA)的药物获批上市。然而,它们均未应用于癌症治疗。这不仅是因为肿瘤微环境的复杂性,还由于RNA本身存在的障碍。到目前为止,人们已经开发出各种策略来提高RNA在癌症治疗中的性能,特别是使用生物源材料的基于纳米颗粒的策略。与使用合成聚合物的策略相比,它们具有更好的相容性和更低的毒性,而研究最广泛的生物源材料是寡核苷酸、外泌体和细胞膜。其独特的特性使它们在内化、内体逃逸以及特异性靶向方面表现出不同的能力。在本文中,我们系统地总结了使用生物源材料的基于RNA的纳米递送系统用于癌症治疗,并且我们相信这篇综述将为参与生物源递送和基于RNA的癌症治疗领域的研究人员提供有价值的参考。